Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone973-242-0005
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings Date5/13/2019 (Estimated)
OptionableOptionable
Neurotrope (NASDAQ:NTRP) Frequently Asked Questions
What is Neurotrope's stock symbol?
Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."
How were Neurotrope's earnings last quarter?
Neurotrope Inc (NASDAQ:NTRP) announced its quarterly earnings data on Monday, March, 11th. The company reported ($0.47) earnings per share for the quarter. View Neurotrope's Earnings History.
When is Neurotrope's next earnings date?
What price target have analysts set for NTRP?
1 Wall Street analysts have issued 1-year price targets for Neurotrope's stock. Their predictions range from $16.00 to $16.00. On average, they expect Neurotrope's share price to reach $16.00 in the next year. This suggests a possible upside of 164.9% from the stock's current price. View Analyst Price Targets for Neurotrope.
What is the consensus analysts' recommendation for Neurotrope?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurotrope.
What are Wall Street analysts saying about Neurotrope stock?
Here are some recent quotes from research analysts about Neurotrope stock:
- 1. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019)
- 2. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (8/17/2018)
Has Neurotrope been receiving favorable news coverage?
Media coverage about NTRP stock has been trending negative recently, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neurotrope earned a news impact score of -2.3 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Neurotrope's key competitors?
Some companies that are related to Neurotrope include Karyopharm Therapeutics (KPTI), Kadmon (KDMN), MannKind (MNKD), Lannett (LCI), Constellation Pharmaceuticals (CNST), Immune Design (IMDZ), Seres Therapeutics (MCRB), Minerva Neurosciences (NERV), Evelo Biosciences (EVLO), American Brivision (Holding) (ABVC), AcelRx Pharmaceuticals (ACRX), Aduro BioTech (ADRO), Xeris Pharmaceuticals (XERS), Kala Pharmaceuticals (KALA) and Kamada (KMDA).
What other stocks do shareholders of Neurotrope own?
Who are Neurotrope's key executives?
Neurotrope's management team includes the folowing people:
- Dr. Charles S. Ryan, CEO & Director (Age 55)
- Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
- Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
- Mr. Jeffrey Benison, Director of Corp. Communications
How do I buy shares of Neurotrope?
Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neurotrope's stock price today?
One share of NTRP stock can currently be purchased for approximately $6.04.
How big of a company is Neurotrope?
Neurotrope has a market capitalization of $78.05 million. Neurotrope employs 6 workers across the globe.
What is Neurotrope's official website?
How can I contact Neurotrope?
Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]
MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
